Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 358

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 358
---
 of any shares of common stock sold through such Sales Agent pursuant to the 2023 Sales Agreement. As of June 30, 2025, the Company had not issued any securities pursuant to the 2023 Sales Agreement.

17

Common Stock Reserved for IssuanceCommon stock reserved for issuance is as follows:  As of June 30,2025Stock options, restricted stock units and performance stock units issued and outstanding12,477,636Reserved for future stock awards or option grants2,265,748Reserved for employee stock purchase plan1,806,244Common stock issuable upon conversion of convertible notes9,963,963 26,513,591

11. Stock-Based Compensation

Stock OptionsThe following table summarizes stock option activity during the six months ended June 30, 2025 (in thousands, except share and per share data):  Number ofAwards Weighted-AverageExercisePriceWeighted-AverageRemainingContractualLife(in Years)AggregateIntrinsicValueOutstanding as of December 31, 2024 10,031,486$18.12 6.5$233,161 Granted1,675,645$47.42  Exercised(1,008,671)$12.85  Canceled and forfeited(112,753)$29.10  Outstanding as of June 30, 2025 10,585,707$23.15 6.6$293,681 Vested and exercisable as of June 30, 2025 6,748,390$16.03 5.5$235,234  The weighted-average grant date fair value per share of stock options granted during the six months ended June 30, 2025 and 2024 was $31.62 and $18.81 per share, respectively. The total intrinsic value of options exercised during the six months ended June 30, 2025 and 2024 was $34.1 million and $6.1 million, respectively. Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that had exercise prices that were lower than the per share fair value of the common stock on the date of exercise. As of June 30, 2025, the total unrecognized stock-based compensation related to unvested stock option awards granted was $85.0 million, which the Company expects to recognize over a weighted-average period of